loader2
Login Open ICICI 3-in-1 Account

Indoco Remedies Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Indoco Remedies Ltd. 06 Nov 2025 11:49 AM

Q2FY26 Quarterly Result Announced for Indoco Remedies Ltd.

Pharmaceuticals company Indoco Remedies announced Q2FY26 results

  • Revenues of Rs 4,293 million, as against Rs 3,946 million, in Q2FY25, registering an 8.8 % revenue growth.
  • EBIDTA for the quarter is at Rs 534 million, compared to Rs 529 million in Q2FY25.
  • PBT: Rs 97.6 million compared to Rs 173.8 million during Q2FY25.
  • PAT: Rs 150.5 million compared to Rs 127.9 million during Q2FY25.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “International formulation and API businesses had a good growth this quarter. The India formulation business performance was impacted due to revision in the GST rates. We are confident of regaining momentum in the coming quarters.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q1FY26 results

  • Revenues of Indoco Remedies are at Rs 3,838 million, as against Rs 3,411 million, in previous quarter, registering 12.5% revenue growth.
  • EBIDTA for the quarter is at Rs 148 million, compared to Rs 35 million in the previous quarter.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “Our 12.5% revenue growth this quarter over last quarter reflects the resilience of our teams, operational excellence and robust strategy. We are confident of sustaining this momentum and making a turnaround going ahead.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • During the fourth quarter of FY 2024-25, revenues of Indoco Remedies are at Rs 3,411 million, as against Rs 4,351 million, same quarter last year.
  • EBIDTA for the quarter is at Rs 35 million, compared to Rs 574 million, same quarter last year.

FY25 Financial Highlights:

  • For the year, revenues are at Rs 14,948 million, as against Rs 17,620 million, same period last year. EBIDTA to net sales for the period is 8.6 % at Rs 1,280 million, compared to 14.6 % at Rs 2,580 million, same period last year.
  • Profit After Tax are at Rs -87 million, compared to Rs 1,166 million, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “While this has been a challenging year for Indoco, there are several optimistic triggers which gives us confidence for a better future, both in the short as well as long term.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q3FY25 results

  • Revenue of Indoco Remedies is at Rs 3,649 million, as against Rs 4,484 million, Q3FY24.
  • EBIDTA to net sales for the quarter is at Rs 201 million, compared to Rs 653 million, Q3FY24.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “Domestic Formulation Business continued to contribute in revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q2FY25 results

  • Revenues: Rs 3,946 million, as against Rs 4,652 million, Q2FY24.
  • EBIDTA: is 13.4 % at Rs 529 million, compared to 15.6% at Rs 724 million, Q2FY24
  • Profit After Tax: 3.2 % at Rs 128 million, compared to 7.1% at Rs 331 million, Q2FY24.

Aditi Panandikar, Managing Director, Indoco Remedies said: “While a good performance by our Domestic Formulation business helped grow revenues, supply constraints have impacted the performance of the International Formulation business. Some of the sites supplying to US and Europe are under structured shutdowns to increase efficiency.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q1FY25 results:

  • During Q1FY25, revenues of Indoco Remedies are at Rs 3,942 million, as against Rs 4,132 million, same quarter last year.
  • EBIDTA to net sales for the quarter is 13.1% at Rs 516 million, compared to 15.2% at Rs 629 million, same quarter last year.
  • Profit After Tax to net sales is 3.8% at Rs 150 million, compared to 6.3% at Rs 259 million, same quarter last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “From licensing out products to front-ending in the US and from a 95% ethically driven domestic business, to selectively chosen products in OTC business, we are undergoing significant strategic transitions at Indoco. Our performance this quarter is reflective of these various strategic moves and I am confident that these will give Indoco a major gain in the long term.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • During the Q4FY24, revenues of Indoco Remedies grew by 1.7% at Rs 4,351 million, as against Rs 4,280 million, same quarter last year.
  • EBIDTA to net sales for the quarter is 13.2% at Rs 574 million, compared to 15.0% at Rs 642 million, same quarter last year.
  • Profit After Tax to net sales is 8.6% at Rs 376 million, compared to 5.9% at Rs 254 million, same quarter last year.

FY24 Financial Highlights:

  • For the year, revenues grew by 7.6% at Rs 17,619 million, as against Rs 16,381 million, same period last year.
  • EBIDTA to net sales for the period is 14.6% at Rs 2,580 million, compared to 17.4% at Rs 2,849 million, same period last year.
  • Profit After Tax to net sales is 6.6% at Rs 1,166 million, compared to 8.6% at Rs 1,414 million, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.”

Result PDF

Pharmaceuticals firm Indoco Remedies announced Q3FY24 results:

Q3FY24

  • Revenue:
    Rs 4,484 million (growth of 9.2% compared to Rs 4,106 million in Q3 of the previous year)
  • EBIDTA:
    Rs 653 million, representing 14.6% of net sales (compared to Rs 617 million or 15.0% of net sales in Q3 of the previous year)
  • Profit After Tax:
    Rs 282 million (before exceptional item), which is comparable to the profit of Rs 279 million reported in the same quarter last year

9MFY24 (Apr-Dec)

  • Revenue:
    Rs 13,268 million (9.6% increase from Rs 12,101 million in the same period last year)
  • EBIDTA:
    Rs 2,006 million, 15.1% of net sales (against Rs 2,207 million, 18.2% of net sales in the previous year)
  • Profit After Tax:
    Rs 873 million (before exceptional item), 6.6% of net sales (compared to 9.6% or Rs 1,160 million in the same period last year)

Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated: "Our Q3 performance is primarily driven by International business particularly US and Emerging Markets, API business and steady performance by India business."

 

 

Result PDF

Pharmaceuticals company Indoco Remedies announced Q1FY24 results:

  • Revenues of Indoco Remedies grew by 5% at Rs 413.2 crore, as against Rs 394.9 crore in Q1FY23.
  • EBIDTA to net sales for Q1FY24 is 15.2% at Rs 62.9 crore, compared to 18.1 % at Rs71.3 crore in Q1FY23.
  • Profit After Tax is at Rs 25.7 crore, compared to Rs 37.5 crore in Q1FY23.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our first quarter results demonstrate good growth in API business, complemented by steady performance in the Domestic Formulation business. We remain optimistic for the rest of the year and are committed to building and further strengthening our position in the market”.

 

Result PDF

Pharmaceuticals company Indoco Remedies announced Q4FY23 & FY23 results:

  • Q4FY23:
    • During Q4FY23, revenues grew by 6.9% at Rs 428.0 crore, as against Rs 400.3 crore in Q4FY22
    • EBIDTA to net sales for Q4FY23 is 15.0% at Rs 64.2 crore, compared to 20.1% at Rs 80.5 crore in Q4FY22
    • For Q4FY23, the Profit After Tax is at Rs 25.4 crore, compared to Rs 40.4 crore in Q4FY22
    • Profit After Tax with other comprehensive income is at Rs 29.7 crore, compared to Rs 35.6 crore in Q4FY22
  • FY23:
    • For FY23, the revenues grew by 9.0% at Rs 1,638.1 crore, as against Rs 1,502.7 crore in FY22
    • EBIDTA to net sales for FY23 is 17.4% at Rs 284.9 crore, compared to 21.8% at Rs 327.0 crore in FY22
    • For FY23, the Profit After Tax is at Rs 141.4 crore, compared to Rs 154.5 crore in FY22
    • Profit After Tax with other comprehensive income is at Rs 142.8 crore, compared to Rs 149.2 crore in FY22

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our performance this year is a function of a predictable performance of India business, free of COVID impact, accompanied by a good performance of Export business”.

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app